Skip to content

Menu

Seyfarth Shaw LLP logo
HomeAboutAuthors
Search
Close

BioLoquitur

The Life Sciences Patent Blog

orphan drugs

Subscribe to orphan drugs
shutterstock_288363524

“Tax Cut and Jobs Act” H.R. 1 Passes House Of Representatives: Provisions To Watch

By Jamaica Szeliga on November 20, 2017
Posted in Biosimilars, Hatch-Waxman, Prosecution, Start Ups, Transactions

BioLoquitur has reported on legislative developments in the past, but never did we expect to discuss a tax bill. Last week, however, the U.S. House of Representatives passed the “Tax Cut and Jobs Act” Bill (H.R. 1) and H.R. 1 deserves a spotlight. After all, one of our goals is to provide…

Stay Connected

RSS Twitter LinkedIn Facebook

Recent Updates

  • Biosimilar IPRs: Timing is Everything . . . But When is The Right Time?
  • Teva Sues FDA Alleging Unlawful Interpretation of the Definition of “First Applicant”
  • USPTO Director Proposes New Patent Eligibility Guidance
  • Tribal Immunity Cannot Be Asserted to Escape IPR Proceedings
  • FDA Approves First Marijuana-Based Drug to Treat Epilepsy

Topics

Archives

Links & Resources

  • ABA Intellectual Property Section
  • American Chemical Society
  • American Intellectual Property Law Association
  • BIO
  • BioCentutry
  • Biospace
  • Biotechnology News — ScienceDaily
  • BioWorld
  • California Peculiarities Employment Law Blog
  • Fierce Biotech
  • Fierce Pharma
  • Genetic Engineering News
  • Patent Trial and Appeal Board (PTAB)
  • Seyfarth PTAB Blog
  • Seyfarth Trade Secrets Blog
  • United States Patent and Trademark Office
Seyfarth Shaw LLP logo
RSS Twitter LinkedIn Facebook
Privacy PolicyAttorney Advertising

About

Seyfarth’s Life Sciences attorneys have a deep understanding of the biotechnology, chemical, pharmaceutical, and nanotechnology industries. We represent an international clientele of innovators and investors working with world-changing technologies. Our clients range from clinical-stage biotechnology companies and multinational pharmaceutical corporations to chemical and nanotechnology companies as well as start-up companies and venture capital firms.

Read More
Copyright © 2022, Seyfarth Shaw LLP. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo